Vaxart ( (VXRT) ) has released its Q3 earnings. Here is a breakdown of the information Vaxart presented to its investors. Vaxart, Inc. is a ...

Protection from shots like the flu vaccine typically takes a couple of weeks to kick in, so getting one now may offer ...

The cooler weather and holidays are fast approaching, along with the deadlines to get vaccinated if you want the most protection from respiratory viruses. "We're currently just on the brink of ...

China has reported seven more H9N2 avian flu infections in humans, mostly involving children and all in people whose symptoms ...

The promising data, which compares favorably to recombinant protein-based vaccines ... 2024 , GSK announced positive Phase 2 headline data from its seasonal influenza mRNA vaccine program based on ...

“The Phase 1 clinical trial is designed to evaluate the safety, reactogenicity, and immunogenicity of ARCT-2304 as a potential vaccine to protect against the highly pathogenic H5N1 avian influenza.” ...

Refusal of COVID-19 and influenza vaccinations was higher among White patients at an allergy/immunology clinic with a diverse patient population.

Meanwhile, COVID activity remained low amid a shift in variant proportions and RSV levels rose in 3 US regions.

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based ... programs currently include pill vaccines designed to protect against coronavirus, norovirus ...